Skip to content

Research

Autism in children: medication shows effect in study

When an autistic child is often severely irritable, suddenly loses control or harms themselves, this can be a considerable strain for the whole family. A new clinical study now examines a further drug treatment option for such situations. The active substance cariprazine showed a greater reduction in pronounced irritability than a placebo in children and adolescents with autism.

The results were published on 22 October 2026 in the Journal of the American Academy of Child & Adolescent Psychiatry. The study provides indications of a possible additional treatment option but is not yet a basis for a general treatment recommendation. It is particularly important that cariprazine is so far not approved in Germany for treating children with autism.

155 autistic children and adolescents studied

For the international clinical study, children and adolescents aged between five and 17 were studied. In total, 155 participants received at least one dose of the study medication or a placebo. The average age was 10.6 years.

The study lasted eight weeks and was randomised and double-blind. This means that participants were assigned to a treatment group at random and neither the families nor the researchers examining them knew who received the active substance and who the dummy medication.

For 152 participants, enough data were available for the efficacy analysis. Of these, 74 received cariprazine and 78 the placebo. The researchers wanted to find out whether the drug can reduce severe irritability and what side effects occur.

Clear improvement in almost 69 percent

After eight weeks, the treating professionals rated irritability as much or very much improved in 68.9 percent of the children in the cariprazine group. In the placebo group this applied to 38 percent. The difference was statistically significant.

Cariprazine also performed better on a standardised questionnaire with which caregivers rated irritability. On the corresponding rating scale, the treatment group improved by an average of 3.7 points more than the placebo group. The statistical effect size was 0.42.

The result is remarkable but must not be equated with a cure or a fundamental change in autism. Only the effect on pronounced irritability was examined. Whether the children as a result became more independent in the long term, experienced less strain or achieved a better quality of life cannot be derived from the main results published.

What severe irritability can mean in autism

In such studies, the medical term irritability includes, among other things, frequent emotional outbursts, pronounced frustration reactions and, in part, aggressive or self-injurious behaviour. Not every autistic child experiences such difficulties, and the causes can be very different.

Pain, lack of sleep, anxiety, overload or difficulty communicating one’s own needs can lie behind intense reactions. A very loud environment or unexpected changes can also play a role. Conspicuous behaviour should therefore not automatically be regarded as a symptom needing treatment without looking for its causes.

Careful assessment is especially important for children who can communicate pain or strain only to a limited extent. Our knowledge article on sensory overload in autism explains more about sensory strain.

Cariprazine is not a drug against autism itself

Cariprazine belongs to the group of atypical antipsychotics. The active substance influences, among other things, certain signalling pathways in the brain in which dopamine and serotonin are involved. In the European Union it is used under the trade name Reagila for treating schizophrenia in adults.

There is currently no approval for children with autism in the EU. The new study therefore also does not mean that parents can obtain a corresponding treatment for their child from now on.

In principle there is no drug that removes autism as a neurodevelopmental condition. Under certain conditions, medications can be used to treat individual serious symptoms or additional conditions.

Such treatment should always be based on clearly defined symptoms and the individual wellbeing of the child. The aim must not be to suppress harmless autistic behaviours or merely to make children appear less conspicuous on the outside.

Which side effects the researchers observed

The safety of the drug was a further focus of the study. In total, adverse events were documented in 51 percent of participants during treatment. Drowsiness and headaches were particularly common.

About 3.9 percent of participants stopped treatment because of adverse events. Severe adverse events were reported in 1.3 percent. The pooled figures concern both study groups and do not in themselves allow a complete assessment of the different risks.

Since the study lasted only eight weeks, the consequences of longer-term use in particular remain open. For medicines from the group of antipsychotics, possible effects on weight, metabolism, movement and alertness, among other things, have to be taken into account.

The results are therefore not sufficient to judge cariprazine in autistic children as safe or suitable in the long term in general. Further regulatory review and a comprehensive benefit-risk assessment would be necessary before any extension of the approval.

Other medications are already in use

Cariprazine is not the first active substance to be studied for treating pronounced irritability in autistic people. For other atypical antipsychotics, in particular risperidone and aripiprazole, several clinical studies already exist.

A systematic review by the international research network Cochrane from 2025 evaluated 17 studies with a total of 1,027 participants. The researchers found indications that certain active substances can reduce irritability in autistic children in the short term.

However, the trustworthiness of the scientific evidence was rated as moderate to very low depending on the outcome studied. Questions on unwanted effects and long-term consequences have also not yet been sufficiently clarified.

The new cariprazine study thus extends the scientific data. It does not prove, however, that the active substance is more effective or better tolerated than medications already studied, because a direct comparison with those products was not part of the study.

Why medication should not be the first answer

International treatment guidelines stress that, for severely distressing behaviours, possible causes should be investigated first. These include physical complaints, psychological strain, communication difficulties and conditions in everyday life.

The British NICE guideline recommends, for example, adapting the environment and the available support services first. Only if these measures are not enough or cannot be implemented because of the severity of the situation should drug treatment with antipsychotics be considered.

Even then, specialist medical supervision, regular review of the benefit and careful monitoring of possible side effects are decisive. A medication does not replace autism-sensitive support and necessary treatment of physical or mental co-occurring conditions.

Which therapeutic options exist in principle is explained in our knowledge article on autism therapy and individual support.

The study was supported by the drug manufacturer

Funding also plays a role in placing the results in context. The pharmaceutical company AbbVie was involved in the planning, conduct, data analysis and interpretation of the study. The company is developing cariprazine for further possible medical uses.

Involvement of the manufacturer does not automatically mean that the results are unreliable. It does make a transparent presentation of possible conflicts of interest and independent review especially important.

The study was carried out using a recognised scientific method and published in a medical journal. Even so, further studies are needed to assess the longer-term benefit, rarer side effects and possible differences between individual patient groups.

What the results mean for families in Germany

For parents of autistic children, the publication does not at first create a new regularly approved treatment option. The study does show, however, that research continues into additional approaches for serious accompanying symptoms.

If a child is often under heavy strain or harms themselves, it should first be examined together with qualified professionals what causes are present. This also includes the question of whether pain, sleep problems, sensory overload or additional mental health conditions play a role.

Parents can record observations over a certain period and pay attention to the situations in which difficulties occur. This information can help in the medical assessment and make it easier to look for suitable support measures.

With recurring sleep problems, it is also worth looking at possible physical and environmental causes. Further advice is provided by our article on sleep problems in autism.

What further studies still have to clarify

The new results are an important research contribution but not yet a final answer to the question of a suitable treatment for severe irritability in autistic children. The benefit observed has to be weighed against possible side effects and the long-term data still missing.

It remains unclear in particular which children benefit in the long term, how stable the improvements are and what risks could arise with longer treatment. Direct comparisons with existing treatment options would also be important.

For the families affected, what ultimately matters is not only an improvement on medical rating scales. What is decisive is whether a child suffers less, can express their needs better and experiences more security, self-determination and quality of life in everyday life.

Sources

Findling, R. L. et al. Cariprazine in the Treatment of Pediatric Patients With Irritability Associated With Autism Spectrum Disorder. Journal of the American Academy of Child & Adolescent Psychiatry, published online on 22 October 2026.

ClinicalTrials.gov. Study registry NCT05439616 on the study of cariprazine in children and adolescents with autism.

European Medicines Agency. Reagila, authorisation and indications of the active substance cariprazine.

Cochrane. Atypical antipsychotics in autism. Systematic review of 21 May 2025.

National Institute for Health and Care Excellence. Autism spectrum disorder in under 19s, support and management. Clinical guideline CG170.

Found a mistake?

If something is factually wrong, out of date or unclear, let us know. You do not have to give any personal details.

Write a noteClose note

What is wrong? A source helps us check it. At least 10 characters.

Only for follow-up questions about this note. Deleted as soon as it has been dealt with. More in the privacy policy.

More news

All news

Newsletter

Subscribe for free. New and revised articles by e-mail. You can unsubscribe at any time.

Newsletter – load the sign-up form by Brevo (opens in a new tab)

When the form loads, Brevo receives technical data such as your IP address. privacy policy

Support Autismus WissenBooks & further reading